The coming of spring has seen the announcement of multiple executive moves in the Asia Pacific region, including a new CEO at Japan's Daiichi Sankyo, while WuXi Apptec and llumina have also made new appointments. Other personnel changes also take place at Shionogi Healthcare and the top of Japan's main regulatory agency.

Significant leadership change is underway at J&J India, with Janssen India chief Sanjiv Navangul on his way out. He will be succeeded by senior J&J hand, Sarthak Ranade, who will need to handle some delicate issues pertaining to Sirturo while also keeping the flow of innovative products from the parent company to India going.

US affiliate of Japanese pharma Astellas taps Pfizer exec for its SVP and Head, Medical Affairs and synthetic biotherapeutics firm Synlogic appoints Janssen VP, GI as its CSO. Dutch multinational Royal DSM chooses new President, DSM Biomedical.

A new COO arrives from Novo Nordisk at Danish immunotherapy firm CytoVac and a J&J Vice President becomes CEO of Xcovery, developer of therapies for advanced tumors. From Eli Lilly, DNA damage response company Artios Pharma adds a CMO.

Genentech SVP now CEO of cancer medicine developer FORMA Therapeutics and a new CEO also for cystic fibrosis treatment firm Synspira Therapeutics. At OTC pharma Perrigo, CFO appointment is announced.

It’s all about development — Amgen Development VP now CTO at rare disease firm Orchard Therapeutics, and Goldman Sachs exec is chief corporate development officer at pharma/cannabis business Tilray. Meanwhile, Genentech early clinical development VP switches to CMO spot at cardio-metabolic and liver disease company NGM Biopharma.

Another busy time for executive moves in the Asia Pacific region, as Amgen China GM joins Henlius, BeiGene appoints new immuno-oncology CMO and Sumitomo Dainippon names a new digital health head. Changes also take place at Ascentage, Harbin Pharma and AdvaMed.

A highly respected industry leader, James Diamond served on the board of Beecham Group and was elected president of the Association of the British Pharmaceutical Industry in 1986.

Targeted protein degradation company C4 Therapeutics welcomes former Novartis development leader as its CMO and immunotherapy technology firm Innovio hires a COO. At Sandoz, the chief executive departs.

Exiting Gilead biology leader lands CSO post at blood cancer company Amphivena Therapeutics. Sanofi moves its Brazil general manager to head China Emerging Markets Business Unit and Mitsubishi Tanabe Pharma America promotes area director to VP, ops and strategy.

The coming of spring has brought with it a plethora of pharma executives changes in the Asia Pacific. Sanofi has a new China GM, Merck China R&D head leaves for a startup and Daiichi Sankyo has a new head for its generics business.

Eli Lilly & Co’s Biology VP takes on SVP, Discovery role at gene regulatory mechanism firm Fulcrum Therapeutics, and Amgen Med Affairs exec becomes CMO at Matinas BioPharma Holdings. At Daiichi Sankyo, R&D leader steps up to Global Head, R&D position.